VICPVicapsys Life Sciences, Inc.

About Vicapsys Life Sciences, Inc. (VICP)

Vicapsys Life Sciences, Inc. (VICP) is a company headquartered in Suwanee, GA, United States whose shares trade over-the-counter on the Pink tier.

ViCapsys is a development stage biotechnology company that is advancing a proprietary localized immune modulator. ViCapsys's technology allows physicians to control the body's immune system in regional areas around an implant, which reduces the risk of transplant rejection or fibrotic overgrowth due to foreign body recognition. The product offers wide ranging benefits in multiple surgical applications including, organ transplants, medical device implantations, and wound healing, without the need for systemic immune suppression. ViCapsys is currently investigating three initial pipeline products treating type 1 diabetes, post-surgical abdominal adhesion formation, and post-trauma keloid formation. The company intends to develop and license other technologies related to immune modulation going forward.

Products and services

ViCapsys is currently investigating three initial pipeline products treating type 1 diabetes, post-surgical abdominal adhesion formation, and post-trauma keloid formation.

VICP key facts

Ticker symbol

VICP

Market tier

Pink

Headquarters

Suwanee, GA, United States

Country of incorporation

US

Year of incorporation

1997

Employees

1

Estimated market cap

$57.30M (as of Aug 1, 2025)

Shares outstanding

32,371,299

Reporting standard

Alternative Reporting Standard

Audit status

Unaudited

Fiscal year end

12/31

Latest filing

Quarterly Report (Mar 31, 2025)

Vicapsys Life Sciences, Inc. leadership

• Federico Pier — CEO
• Jeffrey S Wright — CFO
• Tanya Rhodes — CSO

Explore more: Pink stocks · OTC stocks starting with V